product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human VEGF (aa 207-318) Protein
catalog :
298-VS-005
quantity :
5 ug (also 25 ug)
price :
377 USD
more info or order :
citations: 11
Reference |
---|
Matsuda A, Fukuda S, Matsumoto K, Saito H. Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol. 2008;38:168-75 pubmed
|
Pan Q, Chathery Y, Wu Y, Rathore N, Tong R, Peale F, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007;282:24049-56 pubmed
|
Ball S, Shuttleworth C, Kielty C. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol. 2007;177:489-500 pubmed
|
Neria F, Caramelo C, Peinado H, Gonzalez Pacheco F, Deudero J, De Solis A, et al. Mechanisms of endothelial cell protection by blockade of the JAK2 pathway. Am J Physiol Cell Physiol. 2007;292:C1123-31 pubmed
|
Lake A, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret G, et al. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem. 2006;281:37844-52 pubmed
|
Narazaki M, Tosato G. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood. 2006;107:3892-901 pubmed
|
Sun J, Phung T, Shiojima I, Felske T, Upalakalin J, Feng D, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A. 2005;102:128-33 pubmed
|
Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45:368-74 pubmed
|
image
image 1 :

Recombinant Human VEGF (aa 207-318) Protein Bioactivity
product information
brand :
R&D Systems
master code :
298-VS
SKU :
298-VS-005
product name :
Recombinant Human VEGF (aa 207-318) Protein
description :
The Recombinant Human VEGF (aa 207-318) Protein from R&D Systems is derived from E. coli. The Recombinant Human VEGF (aa 207-318) Protein has been validated for the following applications: Bioactivity.
target :
VEGF
category :
Proteins and Enzymes
sizes available :
5 ug (also 25 ug)
buffer :
Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
conjugate :
Unconjugated
purity :
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
species :
Human
theoretical molecular weight :
14.1 kDa (monomer)
gene symbol :
VEGFA
details of functionality :
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al . (1990) Proc. Natl. Acad. Sci. USA 87 :1323. The ED50 for this effect is 0.75-3.75 ng/mL.
endotoxin note :
<0.01 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
NP_001020541
applications :
Bioactivity
source :
E. coli-derived Recombinant Human VEGF (aa 207-318) Protein
USD :
377
USD 2023 :
377 USD
alt names :
MVCD1, VAS, vascular endothelial growth factor A, Vascular permeability factor, Vasculotropin, VEGFA, VEGF-A, VEGFMGC70609, VPF, VPFvascular endothelial growth factor
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments